Alene Kennedy-Hendricks1, Colleen L Barry2, Elizabeth Stone2, Marcus A Bachhuber3, Emma E McGinty2. 1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD 21205, United States; Johns Hopkins Center for Mental Health and Addiction Policy Research, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD 21205, United States. Electronic address: alene@jhu.edu. 2. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD 21205, United States; Johns Hopkins Center for Mental Health and Addiction Policy Research, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Baltimore, MD 21205, United States. 3. Section of Community and Population Medicine, Louisiana State Health Sciences Center - New Orleans, Department of Medicine, Clinical Sciences Research Building, 533 Bolivar Street, New Orleans, LA 70112, United States.
Abstract
BACKGROUND: Most people with opioid use disorder (OUD) are not treated with FDA-approved medications methadone, buprenorphine, or naltrexone. Expanding capacity for evidence-based OUD medication in primary care is a national priority. No studies have examined primary care trainee physicians' attitudes about these medications. This study surveyed a national sample of primary care trainee physicians and compared their views with those of primary care attending physicians (i.e., those who have completed training). METHODS: Random samples of 1,000 trainee physicians and 1,000 attending physicians specializing in family, internal, or general medicine were selected from the American Medical Association Masterfile. Surveys were mailed February-August 2019. 45 % of eligible trainee physicians and 54 % of eligible attending physicians responded. Chi-square tests were used to compare responses between the groups. RESULTS: Trainee physicians were more likely than attending physicians to agree that treating OUD with medication is more effective than treatment without medication (76 % versus 67 %, p = 0.03). Half of trainee physicians (51 %) expressed interest in treating patients with OUD compared to 20 % of attending physicians. Trainee physicians expressed greater support than attending physicians for policies that loosen restrictions on prescribing OUD medications. CONCLUSIONS: Relative to attending physicians, the emerging cohort of primary care physicians may be more receptive to working with patients with OUD and prescribing medication. Enhancing medical training on OUD and its treatment, exposing clinicians to individuals in recovery from OUD, and increasing support for clinicians that provide medication treatment for OUD may strengthen this group's capacity to respond to the opioid crisis.
BACKGROUND: Most people with opioid use disorder (OUD) are not treated with FDA-approved medications methadone, buprenorphine, or naltrexone. Expanding capacity for evidence-based OUD medication in primary care is a national priority. No studies have examined primary care trainee physicians' attitudes about these medications. This study surveyed a national sample of primary care trainee physicians and compared their views with those of primary care attending physicians (i.e., those who have completed training). METHODS: Random samples of 1,000 trainee physicians and 1,000 attending physicians specializing in family, internal, or general medicine were selected from the American Medical Association Masterfile. Surveys were mailed February-August 2019. 45 % of eligible trainee physicians and 54 % of eligible attending physicians responded. Chi-square tests were used to compare responses between the groups. RESULTS: Trainee physicians were more likely than attending physicians to agree that treating OUD with medication is more effective than treatment without medication (76 % versus 67 %, p = 0.03). Half of trainee physicians (51 %) expressed interest in treating patients with OUD compared to 20 % of attending physicians. Trainee physicians expressed greater support than attending physicians for policies that loosen restrictions on prescribing OUD medications. CONCLUSIONS: Relative to attending physicians, the emerging cohort of primary care physicians may be more receptive to working with patients with OUD and prescribing medication. Enhancing medical training on OUD and its treatment, exposing clinicians to individuals in recovery from OUD, and increasing support for clinicians that provide medication treatment for OUD may strengthen this group's capacity to respond to the opioid crisis.
Authors: C Debra M Furr-Holden; Adam J Milam; Elizabeth D Nesoff; Renee M Johnson; David O Fakunle; Jacky M Jennings; Roland J Thorpe Journal: J Stud Alcohol Drugs Date: 2016-01 Impact factor: 2.582
Authors: Emma E McGinty; Elizabeth M Stone; Alene Kennedy-Hendricks; Marcus A Bachhuber; Colleen L Barry Journal: Ann Intern Med Date: 2020-04-21 Impact factor: 25.391
Authors: Leonieke C van Boekel; Evelien P M Brouwers; Jaap van Weeghel; Henk F L Garretsen Journal: Drug Alcohol Depend Date: 2013-03-13 Impact factor: 4.492
Authors: Alexander C Tsai; Mathew V Kiang; Michael L Barnett; Leo Beletsky; Katherine M Keyes; Emma E McGinty; Laramie R Smith; Steffanie A Strathdee; Sarah E Wakeman; Atheendar S Venkataramani Journal: PLoS Med Date: 2019-11-26 Impact factor: 11.069
Authors: Jessica Heil; Valerie S Ganetsky; Matthew S Salzman; Krystal Hunter; Kaitlan E Baston; Gerard Carroll; Eric Ketcham; Rachel Haroz Journal: West J Emerg Med Date: 2022-04-04
Authors: Elizabeth M Stone; Alene Kennedy-Hendricks; Colleen L Barry; Marcus A Bachhuber; Emma E McGinty Journal: Drug Alcohol Depend Date: 2021-02-16 Impact factor: 4.492
Authors: Alene Kennedy-Hendricks; Emma E McGinty; Amber Summers; Susan Krenn; Michael I Fingerhood; Colleen L Barry Journal: JAMA Netw Open Date: 2022-02-01